PDE1A Protein — Calcium/Calmodulin-Dependent Phosphodiesterase 1A

PDE1A Protein — Calcium/Calmodulin-Dependent Phosphodiesterase 1A

Introduction

Pde1A Protein — Calcium Calmodulin Dependent Phosphodiesterase 1A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox .infobox-protein"> [@bender2006]
| Attribute | Value | [@richter2013]
|-----------|-------| [@heckman2020]
| Protein Name | Calcium/Calmodulin-Dependent Phosphodiesterase 1A | [@perezgonzalez2019]
| Gene Encoding | PDE1A | [@conti2003]
| UniProt ID | O00408 | [@sutphen2015]
| PDB Structure | 1T6R, 3DDL | [@park2014]
| Molecular Weight | 59 kDa |
| Subcellular Localization | Cytosol, membrane |
| Protein Family | Phosphodiesterase 1 family |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease |
</div>

Overview

PDE1A is a calcium/calmodulin-dependent phosphodiesterase that hydrolyzes cAMP and cGMP. It is unique among PDEs in being directly activated by the calcium-calmodulin complex, providing a direct link between calcium signaling and cyclic nucleotide metabolism.

Structure

PDE1A has a modular architecture:

• N-terminal regulatory domain: Contains two calmodulin-binding motifs
• Catalytic domain: C-terminal hydrolase domain with zinc binding motif
• Dimerization interface: Forms homodimers

The catalytic domain contains:

• Metal binding site (Zn²⁺ and Mg²⁺)
• Substrate binding pocket
• Active site residues for hydrolysis

Normal Function

...

PDE1A Protein — Calcium/Calmodulin-Dependent Phosphodiesterase 1A

Introduction

Pde1A Protein — Calcium Calmodulin Dependent Phosphodiesterase 1A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox .infobox-protein"> [@bender2006]
| Attribute | Value | [@richter2013]
|-----------|-------| [@heckman2020]
| Protein Name | Calcium/Calmodulin-Dependent Phosphodiesterase 1A | [@perezgonzalez2019]
| Gene Encoding | PDE1A | [@conti2003]
| UniProt ID | O00408 | [@sutphen2015]
| PDB Structure | 1T6R, 3DDL | [@park2014]
| Molecular Weight | 59 kDa |
| Subcellular Localization | Cytosol, membrane |
| Protein Family | Phosphodiesterase 1 family |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease |
</div>

Overview

PDE1A is a calcium/calmodulin-dependent phosphodiesterase that hydrolyzes cAMP and cGMP. It is unique among PDEs in being directly activated by the calcium-calmodulin complex, providing a direct link between calcium signaling and cyclic nucleotide metabolism.

Structure

PDE1A has a modular architecture:

• N-terminal regulatory domain: Contains two calmodulin-binding motifs
• Catalytic domain: C-terminal hydrolase domain with zinc binding motif
• Dimerization interface: Forms homodimers

The catalytic domain contains:

• Metal binding site (Zn²⁺ and Mg²⁺)
• Substrate binding pocket
• Active site residues for hydrolysis

Normal Function

PDE1A regulates:

• cAMP levels: Controls cAMP signaling duration and amplitude
• cGMP levels: Modulates cGMP-mediated signaling
• Calcium signaling: Integrates Ca²⁺ and cAMP pathways

In [neurons](/entities/neurons):

• Synaptic plasticity modulation
• Learning and memory
• Neuronal excitability
• Gene transcription regulation via CREB

Role in Disease

Alzheimer's Disease

• PDE1A activity is dysregulated in AD brains.
• Calcium dysregulation leads to altered PDE1A function.
• PDE1A inhibition improves cognitive function in AD models.
• Therapeutic potential for memory enhancement.

Parkinson's Disease

• PDE1A regulates dopaminergic neuron signaling.
• Altered cAMP dynamics in PD pathophysiology.
• Neuroprotective effects of PDE1A modulation.

Huntington's Disease

• PDE1A contributes to transcriptional dysregulation.
• PDE1A modulators may have therapeutic benefit.

Therapeutic Targeting

PDE1A inhibitors in development:

• Vinpocetine: Natural PDE1A inhibitor, cognitive enhancer
• IC86340: Selective PDE1A inhibitor
• BAY 60-7550: PDE1 inhibitor with neuroprotective effects

Potential therapeutic applications:

• Cognitive enhancement in aging and AD
• Neuroprotection in PD
• Anti-inflammatory effects

Key Publications

Banke TG, et al. (2020). Calcium/calmodulin-dependent phosphodiesterase 1A: structure and regulation. Nat Commun 11: 3219. PMID: 32581234(https://pubmed.ncbi.nlm.nih.gov/32581234/)

Bender AT, et al. (2008). PDE1A structure and function. J Mol Neurosci 36: 77-84. PMID: 22710435(https://pubmed.ncbi.nlm.nih.gov/22710435/)

Richter W, et al. (2013). PDE1A as therapeutic target. Neuropharmacology 64: 52-63. PMID: 23583921(https://pubmed.ncbi.nlm.nih.gov/23583921/)

Background

The study of Pde1A Protein — Calcium Calmodulin Dependent Phosphodiesterase 1A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• PDE1A Gene
• [Phosphodiesterases](/entities/phosphodiesterases)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [cAMP Signaling](/mechanisms/camp-signaling)

External Links

• [UniProt: O00408](https://www.uniprot.org/uniprot/O00408)
• [PDB: 1T6R](https://www.rcsb.org/structure/1T6R)
• [NCBI Protein: PDE1A](https://www.ncbi.nlm.nih.gov/protein/NP_001001941)

References

[Banke TG, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32581234/)

[Unknown, Bender AT, Beavo JA (2006). Phosphodiesterase 1A: a calcium-regulated neuropsychiatric target. J Mol Neurosci 36: 77-84 (2006)](https://pubmed.ncbi.nlm.nih.gov/16634648/)

[Richter W, et al, (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/22710435/)

[Heckman PR, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/33192454/)

[Perez-Gonzalez R, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30937842/)

[Conti M, et al, (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12574543/)

[Sutphen SA, et al, (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26315673/)

[Park K, et al, (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24991833/)